IPR vs regulatory affairs – interface and strategic aspects MCQs With Answer

Introduction: This quiz set focuses on the interface between intellectual property rights (IPR) and regulatory affairs with strategic considerations relevant to M.Pharm students. It highlights how patenting, data protection, trade secrets and regulatory pathways interact during drug, biologic and medical device development and commercialization in India. Students will encounter questions addressing patentability criteria, Indian-specific provisions (like Section 3(d) and compulsory licensing), regulatory data protection concepts, freedom-to-operate searches, timing strategies for filings and regulatory submissions, and lifecycle management tactics. The questions are designed to deepen understanding of practical choices and risks that influence product exclusivity, market entry timing, and compliance in India’s regulatory and IP environment.

Q1. What is the primary difference between intellectual property rights (IPR) and regulatory affairs in the pharmaceutical context?

• IPR focuses on protecting inventions and commercial exclusivity; regulatory affairs focuses on securing marketing authorization and compliance with safety and efficacy standards.
• IPR enforces clinical trial conduct; regulatory affairs enforces patent law violations.
• IPR manages pharmacovigilance; regulatory affairs negotiates licensing deals.
• IPR prepares product labeling; regulatory affairs writes patents.

Correct Answer: IPR focuses on protecting inventions and commercial exclusivity; regulatory affairs focuses on securing marketing authorization and compliance with safety and efficacy standards.

Q2. What is the standard term of patent protection for pharmaceuticals in India?

• 10 years from grant
• 20 years from date of filing
• 14 years from grant
• Life of the inventor

Correct Answer: 20 years from date of filing

Q3. Which provision of the Indian Patents Act is often cited to prevent “evergreening” of pharmaceutical patents?

• Section 3(d)
• Section 84
• Section 107A
• Section 64

Correct Answer: Section 3(d)

Q4. Under Indian law, a compulsory license for a patented drug can be sought after which minimum period following grant of the patent?

• Immediately after grant
• 3 years from grant
• 10 years from grant
• Only after patent expiry

Correct Answer: 3 years from grant

Q5. Which statement best describes regulatory data exclusivity in India?

• India currently provides a formal data exclusivity period identical to the EU system.
• India does not have a statutory regulatory data exclusivity regime comparable to some developed jurisdictions.
• India mandates permanent exclusivity for all clinical data submitted to regulators.
• India requires data exclusivity only for biologics for 12 years.

Correct Answer: India does not have a statutory regulatory data exclusivity regime comparable to some developed jurisdictions.

Q6. Which statement is correct regarding patent linkage (blocking generic approval until patent expiry) in India?

• India has a formal patent linkage system identical to the US Orange Book.
• India has no formal patent linkage system that automatically blocks marketing authorization for generics.
• India requires a compulsory injunction against the regulator if a patent exists.
• India refuses generic approvals whenever any patent exists anywhere in the world.

Correct Answer: India has no formal patent linkage system that automatically blocks marketing authorization for generics.

Q7. Before filing a regulatory dossier for a new drug in India, which IP-related study is strategically recommended to assess market entry risk?

• Freedom-to-operate (FTO) search and analysis
• Only a novelty search with no claim analysis
• Trademark clearance for the active ingredient name
• Clinical trial meta-analysis

Correct Answer: Freedom-to-operate (FTO) search and analysis

Q8. What is the primary purpose of regulatory data protection where it exists?

• To prevent regulators from using submitted clinical data to approve third‑party generic applications for a limited time.
• To allow patent term extension beyond 50 years.
• To ensure manufacturing process secrets are published in patent documents.
• To automatically grant marketing exclusivity to all new chemical entities for life.

Correct Answer: To prevent regulators from using submitted clinical data to approve third‑party generic applications for a limited time.

Q9. Why is precise claim drafting important for pharmaceutical patent strategy?

• Claims determine the legal scope of patent protection and affect freedom-to-operate and enforcement strength.
• Claims are optional in pharmaceutical patents and rarely used.
• Claims are only useful for trademarks, not patents.
• Claims are confidential and not published with the patent.

Correct Answer: Claims determine the legal scope of patent protection and affect freedom-to-operate and enforcement strength.

Q10. Which of the following best characterizes “evergreening” strategies that may be challenged in India?

• Filing incremental patents for minor modifications that do not show significant therapeutic benefit.
• Patent claims that cover entirely new chemical entities with demonstrated efficacy.
• Filing trademarks for brand names to protect identity.
• Registering trade secrets for manufacturing know‑how.

Correct Answer: Filing incremental patents for minor modifications that do not show significant therapeutic benefit.

Q11. What is the purpose of Form 27 under Indian patent rules?

• To report the working (manufacturing, import, licensing) of a patented invention in India.
• To request expedited patent examination.
• To file an opposition against a patent application.
• To apply for patent term extension.

Correct Answer: To report the working (manufacturing, import, licensing) of a patented invention in India.

Q12. Which legal remedies are commonly available to a patent holder in India for infringement?

• Criminal penalties only
• Civil remedies such as injunctions, damages, and account of profits
• Automatic revocation of the infringer’s business license by the regulator
• No legal remedy is available in India

Correct Answer: Civil remedies such as injunctions, damages, and account of profits

Q13. Is patent term extension (supplementary protection certificate style) generally available in India to compensate for regulatory delays?

• Yes, India provides automatic patent term extension for all pharmaceuticals.
• No, India does not provide a general patent term extension mechanism similar to SPCs.
• Yes, but only for drugs approved before 1990.
• Yes, if the regulator grants data exclusivity.

Correct Answer: No, India does not provide a general patent term extension mechanism similar to SPCs.

Q14. Which authority is primarily responsible for granting marketing authorization for drugs in India?

• Food and Drug Administration (FDA) of USA
• Central Drugs Standard Control Organization (CDSCO)
• European Medicines Agency (EMA)
• World Health Organization (WHO)

Correct Answer: Central Drugs Standard Control Organization (CDSCO)

Q15. For biologic products, what regulatory requirement commonly determines whether a biosimilar can be approved in India?

• Demonstration of comparability in quality, safety and efficacy to the reference biologic through analytical and clinical studies.
• Only a declaration of identical manufacturing process is required.
• Biosimilars are approved solely on the basis of patent expiry of the reference product.
• No data are required; only payment of a fee is sufficient.

Correct Answer: Demonstration of comparability in quality, safety and efficacy to the reference biologic through analytical and clinical studies.

Q16. When might a company prefer trade secret protection over patenting for a pharmaceutical technology?

• When the invention is easily reverse‑engineered from a marketed product.
• When long-term confidential manufacturing know‑how is critical and disclosure in a patent would enable competitors to practice the technology.
• When patent prosecution costs are negligible and disclosure is preferred.
• When a statutory data exclusivity regime prevents disclosure.

Correct Answer: When long-term confidential manufacturing know‑how is critical and disclosure in a patent would enable competitors to practice the technology.

Q17. What does the Bolar exemption allow in the context of regulatory approvals and patents?

• It allows generic manufacturers to use patented inventions only after patent expiry.
• It allows conducting regulatory tests and trials before patent expiry so that marketing approval can be obtained and launch can occur immediately on expiry.
• It prevents any regulatory testing until a patent is fully expired and all royalties paid.
• It cancels the patent automatically when regulatory trials are performed.

Correct Answer: It allows conducting regulatory tests and trials before patent expiry so that marketing approval can be obtained and launch can occur immediately on expiry.

Q18. What is a common international patent filing strategy for pharmaceutical inventions to balance cost and global protection?

• File multiple unrelated national applications without any priority claim.
• File an initial provisional in the home country and then file a PCT application within 12 months to extend decision time and preserve priority.
• Never file any provisional application and wait until clinical approval.
• Rely solely on trademarks to protect the molecule globally.

Correct Answer: File an initial provisional in the home country and then file a PCT application within 12 months to extend decision time and preserve priority.

Q19. Which of the following is true about an “Orange Book” style listing in India?

• India maintains an official “Orange Book” that is identical to the US system.
• India does not operate an Orange Book–style patent listing that automatically links patents to regulatory approvals.
• The Indian Orange Book publishes unpublished trade secrets of manufacturers.
• India requires all patents to be listed in a government-run Orange Book for customs enforcement.

Correct Answer: India does not operate an Orange Book–style patent listing that automatically links patents to regulatory approvals.

Q20. Which of the following are recognized grounds for invalidating a pharmaceutical patent in India?

• Lack of novelty, lack of inventive step, non‑patentable subject matter under Sections 3, or insufficient disclosure
• Failure to register the product with the local chamber of commerce
• Only non-payment of customs duty
• Merely changing the trade name without altering the molecule

Correct Answer: Lack of novelty, lack of inventive step, non‑patentable subject matter under Sections 3, or insufficient disclosure

Download